CONTACT A REP
Patients HCPs
This site is for US Health Care Professionals only.
KISQALI patient portrayal.

KISQALI single-strength tablets make dose reduction simple and convenient

Dose reductions with KISQALI mean no need for new mid-cycle prescriptions or additional costs

Starting dose for early breast cancer: 2 tablets (400 mg). Dose reduction: 1 tablet (200 mg).

For patients with stage II/III HR+/HER2- eBC,

  • KISQALI is given as 400 mg (2 x 200-mg tablets) orally, once daily (3 weeks on, 1 week off) for 36 months with an AI1

    • Review the full Prescribing Information for recommended dosing of selected AI

    • An LHRH agonist should be used concomitantly with AI in men and premenopausal women

  • Dose adjustments for adverse reactions should be made by reducing the number of tablets taken1

    • If dose reduction below 200 mg/day is required, discontinue treatment

    • KISQALI dose modification is recommended based on individual safety and tolerability

    • KISQALI can be taken with or without food

In the NATALEE trial, iDFS benefit was maintained for patients who required KISQALI dose reduction to manage ARs.

Dose adjustment guidance in HR+/HER2- eBC1

resource thumbnail

KISQALI Treatment Guide

A comprehensive guide to treatment with KISQALI, with dedicated sections to support you in treating your patients with HR+/HER2- early or metastatic breast cancer.
Download
resource thumbnail

KISQALI Starter Guide

This guide provides assessment, dosing, and access and support information to help you get your patients started and maintain treatment with KISQALI.
Download
AI=aromatase inhibitor; ALT=alanine aminotransferase; ANC=absolute neutrophil count; AR=adverse reaction; AST=aspartate aminotransferase; BSA=body surface area; CTCAE=Common Terminology Criteria for Adverse Events; CYP3A=cytochrome P450, family 3, subfamily A; ECG=electrocardiogram; iDFS=invasive disease-free survival; ILD=interstitial lung disease; IV=intravenous; LHRH=luteinizing hormone-releasing hormone; LLN=lower limit of normal; QTcF=QT interval corrected by Fridericia’s formula; SCAR=severe cutaneous adverse reaction; SJS=Stevens-Johnson syndrome; TB=total bilirubin; TEN=toxic epidermal necrolysis; ULN=upper limit of normal.
 
Reference: 1. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp.